[
  {
    "ts": null,
    "headline": "Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion",
    "summary": "CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",
    "url": "https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768170600,
      "headline": "Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion",
      "id": 138068851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",
      "url": "https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac"
    }
  },
  {
    "ts": null,
    "headline": "This ETF Is Proof That the Healthcare Rebound Is Real",
    "summary": "Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.",
    "url": "https://finnhub.io/api/news?id=37f4d5b38f1ff502010ff587add70bfce19fea47b3f9d689eddcb7adcf089fbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768147380,
      "headline": "This ETF Is Proof That the Healthcare Rebound Is Real",
      "id": 138075157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.",
      "url": "https://finnhub.io/api/news?id=37f4d5b38f1ff502010ff587add70bfce19fea47b3f9d689eddcb7adcf089fbb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Investor Confidence Up, But Caution Needed",
    "summary": "Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair valuation. See why NVO stock is a hold.",
    "url": "https://finnhub.io/api/news?id=0d1620b04f650690355e85bf9e3c1b0e05b7a1cdf359071b344da6fd9e26b352",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768114660,
      "headline": "Novo Nordisk: Investor Confidence Up, But Caution Needed",
      "id": 138062829,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair valuation. See why NVO stock is a hold.",
      "url": "https://finnhub.io/api/news?id=0d1620b04f650690355e85bf9e3c1b0e05b7a1cdf359071b344da6fd9e26b352"
    }
  }
]